Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2012

View Archived Issues

Suven Life Sciences synthesizes new cognition-enhancing drug candidates

Cell Therapeutics to acquire JAK2 inhibitor from S*Bio

Novel antibody drug fights cancer via new mode of action

U.S. study uncovers new candidate glioma biomarker

Spherix presents results from studies in patients with cardiovascular disease

Proof of concept established for Presidio drug

AT-001 set to enter phase I study in Russia

GSK launches solution for pneumocystis pneumonia in Japan

Two new anticancer therapies presented

RedHill reports RHB-102 bioequivalence data

Advaxis describes two new cancer immunotherapies

Human Genome Sciences receives acquisition offer

Xencor receives milestone payment from CSL

CrystalGenomics reports on phase IIb CG-100649 trial

First patient dosed in new phase I AZD-2820 trial

Michael J. Fox Foundation to sponsor study of Sanofi compound

Senju Pharmaceutical plans new release of ophthalmic solution

Novartis amends U.S. labeling of aliskiren drugs, withdraws Valturna

Pharmaxis product approved in E.U. for cystic fibrosis

Novel orexin OX1 and OX2 receptor antagonists patented

Novel candidate cancer therapies developed by Sanofi

Collaboration yields novel brucellosis vaccines

New antibacterial vaccines patented

Aragon Pharmaceuticals discloses new estrogen receptor modulators

Novel antivirals divulged by Gilead Sciences

Cytokinetics ALS drug candidate gets FDA fast track status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.